Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- FAB689A - Provider product page
- Provider
- Novus Biologicals
- Product name
- Mouse Monoclonal GITR/TNFRSF18 Antibody
- Antibody type
- Monoclonal
- Antigen
- Mouse myeloma cell line NS0-derived recombinant human GITR/TNFRSF18, corresponding to Gln26-Glu161 (Thr43Ala)
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Red dye
- Isotype
- IgG
- Vial size
- 100 Tests
- Storage
- Store at 4°C in the dark.
Submitted references CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.
Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.
Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN, Rigatos G, Papamichail M
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 May 1;13(9):2714-21
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 May 1;13(9):2714-21
Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.
Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H, Breckpot K, Thielemans K, Aerts JL
Journal of leukocyte biology 2007 Jul;82(1):93-105
Journal of leukocyte biology 2007 Jul;82(1):93-105
Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.
Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y
Journal of hepatology 2006 Aug;45(2):254-62
Journal of hepatology 2006 Aug;45(2):254-62
No comments: Submit comment
No validations: Submit validation data